Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI)
with hyperpolarized carbon C13 pyruvate works in finding prostate cancer that exhibits poorly
differentiated or undifferentiated cells (high-grade) and that is restricted to the site of
origin, without evidence of spread (localized) in patients undergoing radical prostatectomy.
Diagnostic procedures, such as MRSI with hyperpolarized carbon C13 pyruvate, may aid in the
diagnosis of prostate cancer and in discriminating high-grade from low-grade prostate cancer
and benign adjacent prostate tissue
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
American Cancer Society, Inc. National Cancer Institute (NCI) National Institute for Biomedical Imaging and Bioengineering (NIBIB)